INMB vs BIIB

For growth investors, INmune Bio, Inc.

(INMB) is the stronger pick with 257. 1% revenue growth year-over-year, versus 1. 4% for Biogen Inc. (BIIB). Biogen Inc. (BIIB) offers the better valuation at 21. 7x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate Biogen Inc. (BIIB) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Biogen Inc.

(BIIB) delivered a total return of -30. 2%, compared to -86. 6% for INmune Bio, Inc. (INMB). Over 10 years, the gap is even starker: BIIB returned -29. 2% versus INMB's -82. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 64β versus INmune Bio, Inc. 's 2. 45β — meaning INMB is approximately 283% more volatile than BIIB relative to the S&P 500. On balance sheet safety, INmune Bio, Inc. (INMB) carries a lower debt/equity ratio of 4% versus 38% for Biogen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), INmune Bio, Inc.

(INMB) is pulling ahead at 257. 1% versus 1. 4% for Biogen Inc. (BIIB). On earnings-per-share growth, the picture is similar: INmune Bio, Inc. grew EPS 11. 8% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, BIIB leads at -1. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Biogen Inc.

(BIIB) is the more profitable company, earning 13. 2% net margin versus -918. 7% for INmune Bio, Inc. — meaning it keeps 13. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIIB leads at 19. 1% versus -617. 4% for INMB. At the gross margin level — before operating expenses — INMB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Biogen Inc.

(BIIB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 64)). INmune Bio, Inc. (INMB) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BIIB: -29. 2%, INMB: -82. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INMB is a small-cap high-growth stock; BIIB is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.